• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?

作者信息

Ambrosy Andrew P, Fudim Marat, Chioncel Ovidiu

机构信息

Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.

Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA.

出版信息

Eur J Heart Fail. 2019 Nov;21(11):1398-1401. doi: 10.1002/ejhf.1555. Epub 2019 Jul 22.

DOI:10.1002/ejhf.1555
PMID:31332924
Abstract
摘要

相似文献

1
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?医疗服务提供者应根据试验入选标准、批准适应症或指南建议来开具沙库巴曲缬沙坦吗？
Eur J Heart Fail. 2019 Nov;21(11):1398-1401. doi: 10.1002/ejhf.1555. Epub 2019 Jul 22.
2
Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.评估心力衰竭患者是否有资格接受沙库巴曲缬沙坦治疗：退伍军人医疗保健系统的见解。
Pharmacotherapy. 2019 Nov;39(11):1053-1059. doi: 10.1002/phar.2328. Epub 2019 Oct 10.
3
Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.沙库巴曲缬沙坦：心力衰竭指南导向药物治疗工具库中的最新药物。
Am J Med. 2017 Jun;130(6):635-639. doi: 10.1016/j.amjmed.2017.02.010. Epub 2017 Mar 9.
4
"Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.“真实世界”中沙库巴曲缬沙坦在未经选择的心衰患者中的使用情况：来自瑞典心衰注册登记研究的数据。
Cardiovasc Drugs Ther. 2019 Jun;33(3):315-322. doi: 10.1007/s10557-019-06873-1.
5
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.与美国沙库巴曲缬沙坦使用相关的患者、提供者和实践特征。
Circ Heart Fail. 2018 Sep;11(9):e005400. doi: 10.1161/CIRCHEARTFAILURE.118.005400.
6
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.沙库巴曲缬沙坦在 ESC-EORP-HFA 心力衰竭长期注册研究中的入选标准和结局：欧洲药品管理局/食品和药物管理局标签、PARADIGM-HF 试验、ESC 指南和真实世界之间的桥梁。
Eur J Heart Fail. 2019 Nov;21(11):1383-1397. doi: 10.1002/ejhf.1532. Epub 2019 Jun 18.
7
[ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].[意大利心脏病学国家学会关于沙库巴曲缬沙坦在心力衰竭患者管理中的立场文件]
G Ital Cardiol (Rome). 2018 Oct;19(10):568-590. doi: 10.1714/2978.29843.
8
Sacubitril/Valsartan: potential treatment for paediatric heart failure.沙库巴曲缬沙坦：小儿心力衰竭的潜在治疗方法。
Cardiol Young. 2018 Sep;28(9):1077-1081. doi: 10.1017/S1047951118001014. Epub 2018 Jul 6.
9
Assessing suitability for sacubitril-valsartan therapy in an Irish cohort: challenges and opportunities.评估爱尔兰队列中沙库巴曲缬沙坦治疗的适用性：挑战与机遇
Ir J Med Sci. 2019 Nov;188(4):1169-1174. doi: 10.1007/s11845-019-01990-0.
10
Sacubitril/Valsartan: Practice Changing Guideline in the Management of Congestive Heart Failure.
J Coll Physicians Surg Pak. 2017 Nov;27(11):733.

引用本文的文献

1
A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure.一种用于识别门诊心力衰竭患者中沙库巴曲缬沙坦超级反应者的简易评分
Front Physiol. 2021 Feb 18;12:642117. doi: 10.3389/fphys.2021.642117. eCollection 2021.
2
Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry.射血分数谱心力衰竭患者沙库巴曲缬沙坦的适应证：来自瑞典心力衰竭注册登记处的真实世界数据。
J Intern Med. 2021 Mar;289(3):369-384. doi: 10.1111/joim.13165. Epub 2020 Sep 1.
3
Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
PIONEER-HF 临床试验人群在因心力衰竭和射血分数降低而住院的患者中的代表性。
Circ Heart Fail. 2020 Apr;13(4):e006645. doi: 10.1161/CIRCHEARTFAILURE.119.006645. Epub 2020 Apr 6.